2082eTiP COPERNICUS: A multinational pragmatic phase II trial of subcutaneous (SC) amivantamab (Ami) in common EGFR-mutated (cEGFRm) NSCLC.
Saved in:
| Title: | 2082eTiP COPERNICUS: A multinational pragmatic phase II trial of subcutaneous (SC) amivantamab (Ami) in common EGFR-mutated (cEGFRm) NSCLC. |
|---|---|
| Authors: | Halmos, B.1 (AUTHOR), Florez, N.2 (AUTHOR), Goldberg, S.B.3 (AUTHOR), Iams, W.4 (AUTHOR), Le, X.5 (AUTHOR), Leal, T.A.6 (AUTHOR), Nguyen, D.7 (AUTHOR), Raez, L.E.8 (AUTHOR), Riess, J.W.9 (AUTHOR), Sabari, J.10 (AUTHOR), Bjork, D.11 (AUTHOR), Stigger, N.12 (AUTHOR), Minchom, A.R.13 (AUTHOR), Xia, K.14 (AUTHOR), Cifuentes, P.15 (AUTHOR), Shanoon, F.15 (AUTHOR), Penton, J.16 (AUTHOR), Hulten, A.17 (AUTHOR), Johnson, M.L.18 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1173-S1173. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2703 |
